الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

نشره PR Newswire · الولايات المتحدة منذ 2 س

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia…

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا

Business Wire

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

Associated Press (Business)

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dow Jones Newswires

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

مشاركة

يستحق القراءة أيضًا

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows